Impact of heart failure on the clinical profile and outcomes in patients with atrial fibrillation treated with rivaroxaban. Data from the EMIR study
Manuel Anguita Sánchez(Mayo Clinic in Florida), Marcelo Sanmartı́n(Universidad de Alcalá), Francisco Javier Parra Jimenez(HM Hospitales), Mohamed Monzer Khanji Khatib(Hospital General de Tomelloso), José Manuel Vázquez‐Rodríguez(Complexo Hospitalario Universitario A Coruña), Juan Cosı́n-Sales(Hospital Arnau de Vilanova), Francisco Marı́n(Instituto Murciano de Investigación Biosanitaria), Alejandro Pérez Cabeza(Centro de Investigación en Red en Enfermedades Cardiovasculares), Román Freixa‐Pamias(Hospital de Sant Joan Despí Moisès Broggi), Gonzalo Barón‐Esquivias(San Raffaele University of Rome), Vivencio Barrios(Apple (Israel)), Iñaki Lekuona(Hospital de Galdakao), Jaime Masjuán(Universidad de Alcalá)
Cited by 3
Related Papers
Guidelines on the management of valvular heart disease (version 2012)
|European Heart Journal|2012|3.6k
Guidelines on the management of valvular heart disease (version 2012)
|European Journal of Cardio-Thoracic Surgery|2012|2k
2016 ESC Position Paper on Cancer Treatments and Cardiovascular Toxicity Developed Under the Auspices of the ESC Committee for Practice Guidelines
|European Journal of Heart Failure|2016|1.8k
Rosuvastatin in Older Patients with Systolic Heart Failure
|New England Journal of Medicine|2007|1.5k
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source
|New England Journal of Medicine|2019|823